Anti-angiogenic alternatives to VEGF blockade by Khan, Kabir A & Bicknell, Roy
 
 
Anti-angiogenic alternatives to VEGF blockade
Khan, Kabir; Bicknell, Roy
DOI:
10.1007/s10585-015-9769-3
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Khan, KA & Bicknell, R 2016, 'Anti-angiogenic alternatives to VEGF blockade', Clinical & Experimental
Metastasis, vol. 33, no. 2, pp. 197-210. https://doi.org/10.1007/s10585-015-9769-3
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Eligibility for repository : checked 15/02/2016
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
REVIEW
Anti-angiogenic alternatives to VEGF blockade
Kabir A. Khan1 • Roy Bicknell1
Received: 1 September 2015 / Accepted: 11 November 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Angiogenesis is a major requirement for tumour
formation and development. Anti-angiogenic treatments
aim to starve the tumour of nutrients and oxygen and also
guard against metastasis. The main anti-angiogenic agents
to date have focused on blocking the pro-angiogenic vas-
cular endothelial growth factors (VEGFs). While this
approach has seen some success and has provided a proof
of principle that such anti-angiogenic agents can be used as
treatment, the overall outcome of VEGF blockade has been
somewhat disappointing. There is a current need for new
strategies in inhibiting tumour angiogenesis; this article will
review current and historical examples in blocking various
membrane receptors and components of the extracellular
matrix important in angiogenesis. Targeting these newly
discovered pro-angiogenic proteins could provide novel
strategies for cancer therapy.
Keywords Angiogenesis  Anti-angiogenesis  Cancer 
Tumour  Therapy
Introduction
Angiogenesis is the growth of new blood vessels from
existing ones, it is an integral part of tumour progres-
sion and metastasis and is one of the original proposed
hallmarks of cancer [1]. The main focus of anti-angio-
genic strategies to date has been on the blockade of
pro-angiogenic growth factors, the most important of
which are the vascular endothelial growth factor
(VEGF) proteins. The first blocking antibodies against
VEGF were created by Genentech [2], and were later
humanised as bevacizumab which became the first anti-
angiogenic treatment gaining FDA approval. Anti-VEGF
therapies have been reviewed extensively and will not
be discussed here [3].
Many problems exist with VEGF inhibition therapy
such as acquired resistance, due to the tumour microenvi-
ronment switching to utilise other pro-angiogenic growth
factors such as fibroblast growth factor-2 (FGF2) [4].
Another caveat in anti-VEGF therapies is the promotion of
metastatic and invasive cancer phenotypes seen in multiple
tumour models [5, 6]. There is also emerging evidence that
VEGF is not only a requirement for active angiogenesis but
also normal vascular homeostasis through autocrine sig-
nalling and VEGF blockade can have negative effects [7].
The requirement of VEGF in non-angiogenic normal adult
tissue function has also been reported, such as VEGF re-
ceptor activation leading to secretion of pro-inflammatory
and pro-thrombogenic molecules from endothelial cells
(ECs) in Wiebel-Palade bodies [8].
There is therefore a growing need for alternative
strategies to halt the angiogenic process; one strategy is by
inhibiting key protein–protein interactions other than
VEGF that are important in angiogenesis. Anti-angiogenic
agents that inhibit enzyme function such as receptor tyr-
osine kinase inhibitors will not be discussed here but have
been extensively reviewed elsewhere [9]. This article will
focus on current attempts and exciting new strategies in
interfering with key extracellular protein–protein interac-
tions as potential therapies against cancer.
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Fibroblast growth factors (FGFs)
FGFs are a family of growth factors that bind to membrane
bound tyrosine kinase FGF receptors. FGF1, FGF2, and
their receptors FGFR1 and FGFR2 are the main FGF
molecules involved in angiogenesis, resulting in endothe-
lial proliferation, migration and differentiation [10]. As
mentioned previously FGF2 has been shown to be an
important mediator of VEGF therapy resistance and this
has been demonstrated clinically in patients with colorectal
cancer treated with bevacizumab [11].
FGFs were first shown to be a targetable component of
tumour angiogenesis in a study which utilised adenoviral
mediated expression of a soluble form of the extracellular
domain (ECD) of FGFR2 fused to an Fc tag. This acts as an
FGF trap inhibiting the growth factor binding to cell bound
FGF receptors, leading to reductions in pancreatic tumour
formation in Rip1Tag2 mice [12]. A more recent version of
this FGF trap was specifically engineered to have high
binding affinity with FGF2 and was administered as a
recombinant protein; this showed an anti-tumour effect in
two different xenograft models [13]. A recent monoclonal
antibody against FGF2 (GAL-F2) has shown promising
anti-angiogenic and anti-tumour effects on a range of dif-
ferent hepatocellular carcinoma xenografts, and its effects
could be increased by VEGF blockade [14]. These anti-
bodies have been licensed to Roche for clinical develop-
ment, highlighting their potential.
The discovery of a natural FGF2 antagonist named
pentraxin-related protein 3 (PTX3) which inhibits FGF2-
FGFR interactions has been utilised to create PTX3 derived
peptides which can inhibit FGF2 dependent angiogenesis
in vitro and in vivo [15]. Recombinant PTX3 or synthetic
peptides could also inhibit tumour growth in prostate
cancer models [16]. More recently PTX3 has been used to
design a small molecule that can act as an extracellular
inhibitor of FGF2 binding [17]. This inhibitor reduced
tumour growth in syngeneic tumours and human xenografts
when administered orally or by intraperitoneal injection.
FGF2 is normally present in high levels but is seques-
tered in the extracellular matrix (ECM) through binding to
heparan sulphate containing proteins [18]. FGF binding
protein (FGF-BP) is secreted by multiple tumours and can
liberate FGF2 from the ECM [19]. The importance of this
protein interaction is shown with siRNA knockdown of
FGF-BP resulting in anti-tumour effects in colon carci-
noma; this provides another possible target for anti-an-
giogenic therapy [20].
Dual blocking of VEGF and FGF2 has been achieved
with the use of a fusion protein containing peptides of both
VEGFA and FGF2, this fusion protein was used to vacci-
nate tumour bearing mice [21]. Tumour growth and tumour
angiogenesis were both impaired, most likely due to the
high titer of antibodies being raised against VEGF and
FGF2 that could be detected in the blood.
Platelet derived growth factors (PDGFs)
PDGFs are growth factors of which there are four members
(PDGFA, B, C and D), these form homodimers or het-
erodimers which are essential for activation of the dimeric
PDGF receptors of which there are two (PDGFRa and b)
[22]. The main pro-angiogenic components are PDGFB
and the pericyte expressed receptor PDGFRb which are
important for pericyte-endothelial interactions [23].
A PDGFB binding DNA aptamer (AX102) has been gen-
erated which inhibits PDGFB-PDGFRb interactions; this
aptamer could cause pericyte loss and vascular regression
in syngeneic mouse tumour models, although this did not
affect overall tumour growth it provided a strategy that
could be used in combination with other anti-angiogenics
[24]. Indeed, a later study used ovarian cancer xenografts
to show that AX102 in combination with bevacizumab
could enhance the anti-tumour effect of bevacizumab alone
[25].
Placental growth factor (PlGF)
PlGF is part of the VEGF family, operates through
VEGFR1 homodimers and is not essential for normal
angiogenesis (PlGF deficient mice are viable and healthy)
but is important in pathological angiogenesis [26]. There
have been conflicting results involving PlGF blockade,
some studies have shown anti-tumour activity against
VEGFR inhibited tumours in mice [27]. Whereas others
have shown PlGF blockade has limited anti-angiogenesis
action in vitro [28] and recent in vivo studies have argued
against its ability to reduce tumour angiogenesis [29].
These effects are likely to be context dependent and PlGF
blocking antibodies are currently undergoing clinical trials.
Angiopoietins
The angiopoietins, of which there are four members (Ang1-
4), are growth factors which bind to the tyrosine kinase
receptors Tie1 and Tie2 [30]. The role of angiopoietins in
angiogenesis is somewhat complex, Ang1 is a strong
agonist and Ang2 a partial agonist of Tie2 [31], in the
presence of high levels of Ang1, Ang2 can act as an
antagonist to Ang1-Tie2 interactions [32]. Ang1 is thought
to mainly stabilise and protect the existing vasculature [33]
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whereas Ang2 prepares endothelium for active angiogen-
esis maintaining a ‘‘plastic’’ state [34]. Ang2 can also
increase endothelial cell (EC) migration and sprouting in a
Tie2 independent manner through integrin signalling [35].
Ang2 is mainly expressed during development and in
areas of the adult that undergo vascular remodelling [36]; it
is also highly expressed in cancer. In the tumour setting a
pattern emerges where the ratio of Ang1 to Ang2 is
increased in favour of Ang2, supporting active angiogen-
esis [37]. These are the main reasons for the drive to
develop anti-angiogenic agents targeting the Ang2-Tie2
interaction. There have been two main methods in blocking
this interaction, namely peptide or antibody based
approaches. The drug trebananib is a peptibody (peptide-Fc
fusion) that contains two peptides per molecule which can
block Ang2 and Ang1 from interacting with Tie2 receptor.
Trebananib inhibits colorectal xenograft tumour growth
and rat corneal vascularisation [38]. Unfortunately tre-
bananib has yielded disappointing results in a phase III
clinical trial for ovarian cancer [39]. More specific inhi-
bitors of Ang2 have been developed including a Tie2-
ECD-Fc ligand trap [40]. In this study directed evolution
using B cell somatic hypermutation was applied to create a
ligand trap that preferentially bound to Ang2 and not Ang1.
This application resulted in a great advance in selective
Ang2 inhibitors, but more importantly the method devel-
oped here could be used in a whole host of different set-
tings to create higher affinity and specificity antibodies or
ligand traps.
Blocking antibodies against Ang2 have been developed
separately by Medimmune (MEDI3617) and Regeneron
(REGN910) [41, 42]. The use of these antibodies inhibited
xenograft tumour growth in both cases and each effect was
enhanced with VEGF blockade, these agents are both
undergoing phase I clinical trials. The success seen with
inhibition of both Ang2 and VEGF has led to the devel-
opment of a bispecific antibody by Roche which can block
both of these growth factors [43]. In a wide range of dif-
ferent tumour xenograft models, this bispecific antibody
showed anti-angiogenic and anti-metastatic properties and
could even cause tumour regression when used in combi-
nation with chemotherapy. There is emerging evidence that
suggests upregulation of Ang2 in some cancers is involved
in tumour resistance to anti-VEGF therapies [44] therefore
combating both of these protein interactions seem to be a
reasonable approach.
Notch receptors and ligands
The evolutionarily conserved Notch signalling pathway in
mammals involves four Notch receptors (Notch1-4) and
five Notch ligands (Jagged 1 and 2 and Delta-like ligands
Dll1, Dll3 and Dll4) [45], Notch 1, 2 and 4 and all ligands
except Dll3 are expressed in ECs [46]. Notch signalling is
vital for angiogenesis; this can be demonstrated in mice
with endothelial specific Notch1 deletion leading to
embryonic lethality, due to defects in vessel maturation and
angiogenesis whereas vasculogenesis is unaffected [47].
Notch signalling is vital for sprouting angiogenesis and the
formation of endothelial tip and stalk cells. Upon VEGF
stimulation tip cells begin to upregulate notch ligands such
as Dll4, which then bind to notch receptors on adjacent
ECs. The activation of notch signalling leads to downreg-
ulation of VEGF receptor 1 and 2 (VEGFR1 and 2) and
formation of a stalk cell phenotype [48, 49]. Dll4 has been
found to be upregulated in the vessels of tumour xenografts
and also in the vessels of human tumours suggesting a good
target for anti-angiogenic agents [50, 51].
Notch protein interactions have been successfully tar-
geted numerous times by different methods. Dll4 blockade
using monoclonal antibodies caused ECs in vitro and
in vivo to display increased sprouting and increased pro-
liferation, most likely due to the lack of inhibitory cues
from a tip cell, therefore all ECs under VEGF stimulation
become of the tip cell phenotype. This Dll4 inhibition was
anti-angiogenic and showed anti-tumour effects in six
different tumour models [52]. Notch-Dll4 protein interac-
tion inhibition was also achieved by use of a soluble Dll4
ECD fused to an Fc tag (Dll4-ECD-Fc) in two separate
studies, this approach phenocopied effects on tumour
angiogenesis seen with the antibody blocking strategy [53,
54]. Despite increasing vessel branching and sprouting, the
anti-angiogenic effects seen with inhibition of the Notch
pathway in the above examples, are likely due to formation
of non-functioning vasculature which leads to poor perfu-
sion and hypoxia in tumour tissue [55]. Targeting the notch
pathway using Notch1 specific antibodies has also been
shown to have similar anti-angiogenic and anti-tumour
effects in two different xenograft models [56]. Soluble
versions of the Notch1 receptor have also been developed,
utilising the whole of the Notch1 ECD fused to an Fc tag
(Notch1 decoy) this had anti-angiogenic effects in mouse
tumour xenografts [57]. More recently Notch decoys con-
taining domains that bind to Jagged, Dll1/Dll4 or both have
been created [58]. The Dll1/Dll4 binding decoy causes
vessel hypersprouting in vitro, this fits with the already
proposed model of Dll1 and Dll4 Notch signalling resulting
in inhibitory signals inducing cells into a stalk cell phe-
notype. This decoy also has anti-tumour effects most likely
due to mechanisms already discussed with Dll4 blockade.
The notch decoy which blocks Jagged1 and Jagged2
reduced EC sprouting in vitro and retinal angiogenesis
in vivo. This decoy also reduced tumour growth due to
decreased tissue perfusion, reduced coverage of pericytes
and reduced sprouting. The authors propose a mechanism
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where Notch1-Jagged signalling is pro-angiogenic by
downregulating expression of the decoy soluble VEGFR1
receptor and is important for endothelium to associate with
pericytes aiding in vessel maturation.
Although blocking Dll4 has shown anti-tumour
responses in these pre-clinical models, the aberrant effects
of chronic Dll4 inhibition have also been investigated.
Sustained treatment with anti-Dll4 antibodies result in
abnormal liver pathology and can give rise to vascular
neoplasms in various species including monkeys, rats and
mice [59]. Similarly low frequency genetic loss of Notch1
in adult mice leads to increased endothelial proliferation
and the formation of vascular tumours [60]. Nevertheless
humanised anti-Dll4 antibodies (demcizumab) are cur-
rently undergoing clinical trial evaluation in various
tumour types. Alternative approaches could include
specifically inhibiting Notch-Jagged protein interactions
without inhibiting Notch Dll1/Dll4, as inhibiting in this
way does not cause hypersprouting and hyperproliferation
which is the likely mechanism leading to vascular
neoplasms.
Integrins
Integrins consist of a and b subunits which dimerise to
mainly bind components of the ECM and elicit signal
transduction events. In endothelium the major integrins and
the most targeted are a5b1, avb3 and avb5 which are
upregulated during active angiogenesis [61, 62]. a5b1 and
avb5 bind to fibronectin and vitronectin respectively,
whereas avb3 has a larger range of interacting proteins,
including fibronectin, vitronectin, and fibrinogen among
others [63]. These integrins bind via the Arginine-Glycine-
Aspartic acid (RGD) motif which was first discovered to be
important in fibronectin [64]. avb3 is required for angio-
genesis induced by FGF2 or TNFa and avb5 is required for
VEGF and TGFa activation, cyclic RGD peptides or
antibodies against either integrin could block growth factor
induced angiogenesis [65].
The findings that avb3 is highly expressed on activated
endothelium during angiogenesis and has high expression
on tumour vasculature gives it targeting potential [66, 67].
Humanised anti-avb3 antibodies (Vitaxin or etaricizumab)
have yielded promising preclinical and phase I results [68,
69] but unfortunately have had little effect on disease
progression in phase II trials in melanoma [70]. A cyclic
RGD peptide (cilengitide) that blocks both avb3 and avb5
protein interactions has shown preclinical success in mouse
models of breast cancer [71, 72]. In a recent phase III trial
of newly diagnosed glioblastoma, cilengitide was com-
bined with chemoradiotherapy which resulted in no sig-
nificant benefit and the subsequent suggestion by the
authors to halt further cilengitide development in its current
form for cancer therapy [73]. The inhibition of avb3 and
avb5 integrins has so far been disappointing clinically and
it is unclear whether inhibiting these integrins will yield
significant clinical benefit. It is interesting to note that pro-
tumour and pro-angiogenic effects are seen with RGD
peptide inhibitors of avb3 and avb5 at low concentrations
in mouse models [74]. More recently cilengitide has been
used in combination with the calcium channel blocker
verapamil to promote tumour vascularisation in lung and
pancreatic mouse tumours [75]. This allowed better per-
fusion and delivery of chemotherapeutic agents resulting in
reductions in tumour growth and metastasis.
Antibodies blocking a5b1 (volociximab) can induce
apoptosis of proliferating ECs in vitro and could inhibit
choroid vascularisation in cynomolgus monkeys [76]. As
volociximab does not recognise murine a5b1, rat anti-
mouse monoclonal antibodies have been generated which
have anti-tumour effects in mouse tumour models [77].
Volociximab is currently undergoing further trials, but
Phase I trials in non-small cell lung cancer have shown
partial response in some patients [78].
VE-cadherin
VE-cadherin is an endothelial specific adhesion molecule
found at cell–cell contacts where it can bind to other VE-
cadherins on neighbouring cells forming adherens junc-
tions (AJs) [79]. VE-cadherin gene expression has been
shown to be upregulated in tumour angiogenesis and is
upregulated in response to FGF2 [80]. Monoclonal anti-
bodies against VE-cadherin have shown reductions in
tumour growth without causing vascular permeability [81].
Interestingly an antibody that specifically binds to a region
of VE-cadherin that is only exposed when ECs are
undergoing neoangiogenesis has been developed, this
antibody could still disrupt AJs and offers a way of
inhibiting VE-cadherin function in active angiogenesis
[82]. The first three cadherin domains of VE-cadherin have
displayed anti-angiogenic properties in a HUVEC tube
formation assay and a colon carcinoma xenograft model
[83]. This soluble VE-cadherin ECD most likely disrupts
VE-cadherin homotypic binding and endothelial cell–cell
contacts.
Ephrins and Eph receptors
The tyrosine kinase Eph receptors consist of 15 different
members which bind differentially and promiscuously to 9
membrane bound ligands to elicit a range of effects such as
migration, proliferation, survival and tissue patterning [84].
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Signalling events can occur through the Eph receptor
(forwards) or through the ephrin ligand (reverse) [85]. In
angiogenesis two main protein interactions take place,
EphA2-ephrinA1 and EphB4-ephrinB2, these are the most
studied and most targeted [86].
EphrinA1 is expressed at sites of vasculogenesis in the
developing embryo [87] and is also expressed on the vas-
culature and on tumour cells of mouse xenografts and
various human tumours, including those of breast cancer
patients [88]. EphrinA1 expression and subsequent EphA2
activation has been shown to be upregulated by VEGF.
Blocking this protein interaction using an EphA2-ECD-Fc
decoy reduced VEGF induced but not FGF2 induced EC
function [89]. The use of EphA2-ECD-Fc has been shown
to reduce tumour angiogenesis in vivo in Rip1Tag2 pan-
creatic and 4T1 breast tumour models; it also had inhibi-
tory effects on bovine microvascular cells in vitro but not
on the 4T1 tumour cells in culture demonstrating vascu-
lature specific effects [90]. The EphA2-ECD-Fc also had
anti-tumour and anti-angiogenic effects on human xeno-
grafts, and in orthotopic models of pancreatic cancer [91].
EphB4-ephrinB2 interactions have been implicated in
angiogenesis and vasculogenesis, ephrinB2 is essential for
correct artery formation and its receptor EphB4 correct
vein formation. This process is dependent upon forward
and reverse signalling of both proteins [92]. In tumour
angiogenesis the expression of EphB4 on tumour cells has
been shown to be important in interacting with ephrinB2 on
ECs and promoting tumour angiogenesis [93]. Furthermore
ephrinB2 reverse signalling is required for EC tip guidance
by internalisation and subsequent activation of VEGFR2;
ephrinB2 signalling deficiency results in decreased tip cell
formation and is therefore an attractive target [94]. The
most promising approach inhibiting this interaction so far
involves a soluble EphB4 ECD conjugated to human serum
albumin (EphB4-ECD-HSA), this has shown anti-angio-
genic effects on pancreatic tumours in Rip1-Tag2 mice,
which could be improved with Dll4-Notch blockade using
Dll4-ECD-Fc [95]. EphB4-ECD-HSA can also have inhi-
bitory effects on some tumour cells and has led to complete
remission in bladder cancer xenografts with bevacizumab
treatment [96]. EphB4-ECD-HSA is currently undergoing
phase I clinical evaluation.
CLEC14A
CLEC14A is a tumour endothelial marker upregulated in
the vasculature of a range of different tumour types com-
pared to healthy tissue [97]. Our group and Zanivan et al.
have independently shown that CLEC14A binds to an
endothelial specific ECM protein multimerin-2 (MMRN2)
[98, 99]. siRNA knockdown of CLEC14A or MMRN2
results in impaired angiogenesis in vitro [100, 97], fur-
thermore both of these proteins have been shown to be
upregulated with tumour progression in spontaneous mouse
models [99]. These reasons make the CLEC14A-MMRN2
interaction an attractive one for anti-angiogenic targeting.
We have recently identified a monoclonal antibody against
CLEC14A that can inhibit it from binding to MMRN2.
This blocking antibody has detrimental effects on angio-
genesis in vitro in tube formation and spheroid sprouting
assays, but more importantly this antibody can also disrupt
tumour angiogenesis in a Lewis lung carcinoma (LLC)
model leading to reductions in tumour growth [98]. Anti-
bodies raised specifically against the C-type lectin domain
of CLEC14A have also been shown to have anti-angio-
genic effects; we hypothesise that these may also interrupt
the CLEC14A-MMRN2 interaction [101].
TEM8
TEM8 or ANTXR1 is an anthrax toxin receptor which has
been identified as a tumour endothelial marker [102].
TEM8 has been shown to interact with the a3 subunit of
collagen VI; this interaction partner was also found to be
upregulated in tumour endothelium, suggesting that the
interaction may be a target for anti-angiogenics [103].
TEM8 knockout mice develop relatively normally but
display impaired angiogenesis in tumour xenografts lead-
ing to reduced tumour growth [104]. When TEM8 is
blocked with monoclonal antibodies, this too results in
reductions in tumour xenograft growth with melanoma
showing the highest efficacies [105]. TEM8 blockade was
most effective when combined with VEGF blockade and
chemotherapy. The extracellular domain of TEM8 fused to
an Fc tag (TEM8-ECD-Fc) also has anti-angiogenic effects
and inhibits growth in tumour xenografts [106]. This is
likely due to the TEM8-ECD-Fc binding to TEM8 ligands
and inhibiting membrane bound TEM8 interactions.
MCAM (CD146)
MCAM or melanoma cell adhesion molecule (CD146) is a
VEGFR2 co-receptor, has implications in tumour angio-
genesis and is found to be upregulated in a wide range of
different cancers [107]. Mice deficient in endothelial
MCAM develop normal vasculature but display defects in
tumour growth [108]. A number of protein interactors have
been identified for MCAM including the ECM protein
laminin-411 [109]. More recently MCAM has been shown
to interact with the neuronal guidance protein netrin-1, this
interaction was shown as pro-angiogenic, enhancing EC
proliferation, migration and tube formation [110]. A
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monoclonal antibody against MCAM could block this
interaction and the interaction with VEGFR2. The same
monoclonal antibody has previously been demonstrated to
have anti-angiogenic and anti-tumour effects in xenograft
models which could be enhanced with addition of beva-
cizumab [111]. Disrupting the MCAM-netrin-1 and
MCAM-VEGFR2 interactions are the likely mechanisms
of this effect, although the authors did not test whether the
antibody disrupts MCAM binding to other known ligands.
Endoglin
Endoglin or CD105 is a dimeric co-receptor for trans-
forming growth factor-b (TGF-b) and is expressed on adult
endothelium and some haematopoietic cells including
proerythroblasts [112, 113]. Endoglin deficient mice die at
embryonic day 11.5 due to defects in angiogenesis and
vessel remodelling but display no defects in vasculogenesis
[114]. Endoglin is highly expressed on proliferating
endothelium including that of a range of human tumours
[115]. It is upregulated in response to hypoxia and VEGF
blockade, for these reasons endoglin poses another attrac-
tive target for therapies [116, 117]. Tumour xenografts
treated with anti-endoglin monoclonal antibodies showed
anti-angiogenic effects which could be enhanced with
chemotherapy, this antibody was used to create a human
chimeric antibody named TRC105 [118]. While TRC105
has been linked with antibody directed cell cytotoxicity
(ADCC) [119], a recent study has shown TRC105 to inhibit
BMP-9 binding to endoglin and the BMP receptor com-
plex, resulting in inhibition of SMAD1 signalling leading
to arrest in vessel formation, suggesting a possible mech-
anism of action [120]. TRC105 shows anti-angiogenic
properties in vitro which is enhanced when combined with
bevacizumab [121]. Phase I trials of TRC105 in combi-
nation with bevacizumab in various advanced solid
tumours look to be promising, with some patients dis-
playing reductions in tumour volume, further trials are
underway [122].
Advantages in protein–protein inhibition
Higher specificity
If a protein interaction is targeted then both components
will need to be expressed and important for pathological
angiogenesis. A good example is the co-expression of
CLEC14A and MMRN2. If MMRN2 is important for other
vascular functions, which is highly likely, then by specif-
ically inhibiting its interaction with CLEC14A that only
appears to be important in neoangiogenesis, aberrant
effects elsewhere are likely to be minimalized.
Expression in tumour cells
While high specificity in tumour angiogenesis is a desired
characteristic, this is not the case if the interaction is also
important in tumour cells as seen with some Eph-ephrin
and integrin interactions.
Better tolerance
Many of the strategies in inhibiting protein interactions
discussed in this review involve using human antibodies or
decoys derived from human sequences, as these are bio-
logical agents they are likely to be better tolerated in
patients and less likely to elicit an immune response.
Ease of design
When a potential pro-angiogenic protein interaction is
revealed, the use of decoys or antibodies directed against
either protein can be easier than screening small molecules
that may inhibit a receptor or ligand function (discussed in
Fig. 1). The fact that there are currently no specific TIE2
small molecule kinase inhibitors, but there are many pro-
tein based approaches in disrupting its interactions
emphasises this point.
Disadvantages in protein–protein inhibition
Possible off target effects
In theory specificities may be increased using protein–
protein interaction strategies as described above, in reality
this is limited by the knowledge of a certain interaction
pathway. It is important to note that some patients in the
TRC105 trial displayed hypoproliferative anemia due to
endoglin expression on proerythroblasts [122]. Some rel-
atively new interactions with little known about them
could be important for other functions within an adult
resulting in off target effects. Furthermore inhibiting a
certain receptor or ligand has the potential to disrupt
interactions with other partner proteins that may be cur-
rently unknown. Therefore with more basic research into
newly discovered angiogenic pathways, these important
functions can be dissected. The need for good preclinical
models is also key here, with careful attention being given
to possible side effects or abnormalities occurring in other
tissues other than tumours.
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Potential for resistance
As is seen with VEGF blockade, the potential for the
tumour microenvironment to become resistant to certain
therapies is high. As there are a large range of pro-angio-
genic interactions and pathways it would be difficult and
unfeasible to target them all. Hence the use of easily
detectable biomarkers in cancer patients undergoing treat-
ment will be of great benefit, to determine the best strate-
gies for alternative therapies when and if resistance occurs.
Emerging approaches
The majority of work in inhibiting protein interactions has
been through the use of antibodies binding and blocking
normal protein function. Indeed this strategy has had the
most success clinically, with a large number of antibodies
targeting various angiogenic factors entering clinical trials
(Table 1). The future of antibody therapy will most likely
involve the ability to bind more than one antigen. This has
been seen with bispecific antibodies and more recently the
creation of zybodies, that can bind up to five different
targets by the use of peptides added to traditional antibody
scaffolds [124]. This adds the capability to target multiple
pro-angiogenic molecules using only one therapy, which
would be advantageous as many of the discussed examples
display increased efficacy when combined with VEGF
blockade.
One of the major problems with therapeutic antibodies
are the high costs associated with them. These costs are
attributed to the expense in manufacturing and putting
them through clinical trials. Future strategies may instead
include the use of vaccinations using recombinant pro-
teins of certain receptors or ligands, resulting in anti-
bodies being raised against this target in the body rather
than being administered. The quantity of recombinant
protein used would be a fraction of that which is needed
in antibody therapy. Such vaccinations as described pre-
viously for VEGF and FGF-2 could perhaps include
recombinant proteins containing a number of different
regions or epitopes from proteins involved in angiogene-
sis. By fusing domains of different proteins together this
produces a new chimeric protein that could be seen as
non-self and will most likely result in better immune
responses, while still containing regions identical to the
wild type proteins that the immune system can recognize.
The use of epitopes in vaccines that are already known to
give good anti-angiogenic blocking antibodies would be a
good strategy. These epitopes in interacting regions are
more likely to be immunogenic and are also solvent
exposed, facing out into the environment allowing better
accessibility for antibody recognition. Other advantages in
the vaccine approach would be the creation of memory B
cells that could be activated with tumour reoccurrence
[125].
Future of anti-angiogenics
There is recent evidence that other routes to tumour vas-
cularisation exist, such as the ability of tumour cells to
hijack existing vasculature, known as vessel co-option. b1
integrins are thought to be involved in vessel co-option in
brain metastases, when b1 was blocked or deleted in mouse
models, tumour cells could no longer adhere to the vascular
basement membrane reducing metastasis development
[126]. The role of the axon guidance molecule L1CAM has
also been linked to vessel co-option in brain metastasis
allowing cells to spread along capillaries [127]. Likewise
the emerging role of endothelial progenitor cells recruited
from the bone marrow aiding tumour angiogenesis and
Fig. 1 Strategies in disrupting protein–protein interactions. Antibod-
ies against either protein (if possible raised against domains known to
be involved in interaction). If the target protein is ubiquitously
expressed then the Fc region of the monoclonal antibody can be
mutated to block immune cell recognition, therefore only the blocking
function of the antibody will likely remain. Fc fusion traps or decoys,
by fusing the ECD of either the ligand or receptor to an Fc tag and
producing a soluble version which can bind but elicit no signalling
response. Peptides or peptibodies these would require a linear binding
site to be determined which can then be synthesised as a peptide,
alternatively high throughput screening of peptide libraries could be
used. Small molecule inhibitors, this approach is more difficult and
would most likely rely on a structure being solved of the protein
interaction complex so molecules can be designed. Alternatively, high
throughput screening could be used on libraries of drug compounds.
DNA or RNA Aptamers that can inhibit protein interactions such as
pegaptanib which binds to VEGFA 165 isoform [123]. Advantages
include the ease and low cost of synthesis of such agents
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vasculogenesis is also another point to consider [128].
Elucidating the molecular mechanisms and protein inter-
actions required for both of these events will likely lead to
the development of therapies against them.
A major problem in cancer research is the lack of useful
animal models. Animal models of cancer have been
developed to give fast growing tumours to permit experi-
mentation within an acceptable time frame. Such tumours
are very different from real human cancers that are often
heterogeneous and develop over long periods of time. It is
clear that many anti-angiogenic agents have had preclinical
success in these mouse models but this rarely translates to
the clinic, there is evidently a growing need for new
models that better mimic tumours seen in patients espe-
cially in metastatic disease [129].
Differences in homology of certain targeting molecules
between human and mouse and the lack of cross reactive
antibodies are also a limiting factor for preclinical
models. The generation of humanised mouse models may
be of benefit as has been achieved for VEGFA and
endoglin [130] [131]. With the recent advances in
genomic editing technology such as clustered regularly
interspaced short palindromic repeats (CRISPR) this will
likely lead to the development of more humanised mouse
models [132].
Anti-angiogenic therapy was originally hailed as a
blanket approach that could be used against any solid
tumour; however evidence suggests that the expression
profile of vasculature between different tumour types can
be diverse. The differential expression of novel proteins
has been shown in tumour endothelium from lung and
colorectal cancer [133, 134]. Differences have even been
shown between the vasculature of breast cancers of the
same type, where two subtypes could be made by simi-
larities in clusters of gene expression [135]. With advances
in personalised medicine and whole transcriptome
sequencing, it is not implausible to imagine a future ther-
apy strategy that targets against various pro-angiogenic
processes being utilised by a particular patient’s tumour
vasculature. Targeting multiple proteins in combination
with VEGF blockade, especially those thought to be
important in VEGF resistance, such as Ang2 and FGF2 will
likely result in better patient outcomes. With the discovery
of more pro-angiogenic interactions that are important in
tumour formation, we will likely gain a larger range of
targets in our arsenal against cancer.
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